*Disclaimer

IMUGENE LIMITED (ASX: IMU)

🔗 📄 📈

IMU: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration

IMUGENE LIMITED

2023-07-20 09:46:00

IMU: Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US

IMUGENE LIMITED

2023-07-19 09:51:00

IMU: New Dose Escalation in Phase I Clinical Trial of CHECKvacc

IMUGENE LIMITED

2023-07-07 08:56:00

IMU: HER-Vaxx induced antibodies correlated with tumour reduction

IMUGENE LIMITED

2023-06-30 08:40:00

IMU: Imugene PD1-Vaxx patent extended to 2040

IMUGENE LIMITED

2023-06-29 08:39:00

IMU: Imugene Advances VAXINIA MAST Trial to Next IV Cohorts

IMUGENE LIMITED

2023-06-09 08:56:00

IMU: Imugene doses first combination patient in PD1-Vaxx trial

IMUGENE LIMITED

2023-06-01 09:02:00

IMU: FDA clears Imugene IND for onCARlytics first-in-class study

IMUGENE LIMITED

2023-05-19 08:35:00

IMU: onCARlytics with ARTEMIS T cells show anti-tumour activity

IMUGENE LIMITED

2023-05-18 09:04:00

IMU: onCARlytics with Artemis T cells abstract presented at ASGCT

IMUGENE LIMITED

2023-05-03 08:37:00

IMU: Imugene receives $12.6m R&D tax refund

IMUGENE LIMITED

2023-04-26 09:00:00

IMU: Imugene Images and Follows CHECKVacc in TNBC Patients

IMUGENE LIMITED

2023-04-20 08:33:00

IMU: First patients dosed in IT & IV cohort 3 of VAXINIA trial

IMUGENE LIMITED

2023-04-05 09:35:00

IMU: First Patients Dosed in Combination Study of VAXINIA

IMUGENE LIMITED

2023-03-03 09:41:00

IMU: Imugene PD1-Vaxx Immunotherapy Patent Granted in the US

IMUGENE LIMITED

2023-02-10 08:41:00

IMU: Imugene VAXINIA trial advances to Combination Cohort

IMUGENE LIMITED

2023-02-02 09:50:00

IMU: Imugene Receives Vaxinia Ethics Approval In Australia

IMUGENE LIMITED

  1. Tasman Oncology Research, a comprehensive cancer hospital, receives Human Research Ethics Committee approval for Phase I human trial of anti-cancer oncolytic virotherapy VAXINIA.
  2. Patient screening scheduled to commence in January.
  3. Ethics approval process represents first independent review of VAXINIA pre-clinical safety and efficacy data in Australia.

2023-01-09 09:31:00